WCN26-2975 Improvement of Proteinuria with Smoking Cessation and SGLT2 Inhibitor in a Patient with Smoking-Related Nodular Glomerulosclerosis: A Case Report

Read full text Summarise with VIRAT
Authors: Eri Eto, Miyuki Imasato, Maki Minami, Goh Kodama, Kei Fukami
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Smoking-related nodular glomerulosclerosis (SRNG) is a distinct clinicopathologic entity that resembles diabetic nephropathy but occurs in patients without diabetes, often associated with long-term smoking and hypertension. Approximately 40% of SRNG patients progress to end-stage renal disease (ESRD) within five years. Recent studies from our department demonstrated marked overexpression of advanced glycation end products (AGEs) and their receptor (RAGE) in glomeruli and arterial walls of SRNG patients.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Renal Diseases and Glomerulopathies Advanced Glycation End Products research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104309–104309
Publication date
25 March 2026
Language
EN